Floatz logo

Irinotecan

Recurrent Diffuse Large B-Cell Lymphoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Ifosfamide
University of California, Davis
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →